We reply within 24 hoursLeave an inquiryRemote review
Korea
Cancer
Center
Request a reviewBook a call

Treatments

Proton therapy

Protons stop inside the tumour, and almost no radiation carries on beyond it. That is why proton therapy is used next to the spinal cord, brain and eyes, and in growing children.

Request a review Book a call
Type
Radiation (particle) therapy
Cancers
Childhood cancers · head-and-neck, eye and brain tumours · liver cancer · selected lung cancers · tumours near the spine
Anaesthesia
None (sedation possible for children)
Sessions
10–35, five per week
Hospital stay
Outpatient
Stay in Korea
4–7 weeks
Cost
Insured for some cancers in Korea (international patients pay the hospital's rate) · confirmed by quote
Quick answer

Proton therapy accelerates hydrogen nuclei (protons) and directs them at the tumour. Because protons stop at a set depth, tissue beyond the tumour receives almost no radiation.

What it is

Proton therapy accelerates hydrogen nuclei (protons) and directs them at the tumour. Because protons stop at a set depth, tissue beyond the tumour receives almost no radiation.

Its effect on the cancer is similar to conventional radiation; its strength lies in sparing what surrounds the tumour.

Who it suits

It is used for childhood cancers where a growing body must be protected, tumours next to the eye, brain or spinal cord, head-and-neck cancer, liver cancer, and selected lung and oesophageal cancers. It is also considered when a recurrence has to be re-irradiated.

It is not a standard treatment for cancer that has spread to several organs, or for blood cancers. The remote review answers based on your stage and the tumour's location.

How it proceeds

Simulation and planning take one to two weeks, followed by 10–35 sessions, five days a week. Each session takes about 30 minutes including set-up.

Children may need sedation to stay still, so a paediatric anaesthesia team is on hand. The concierge arranges family accommodation and schedules.

Duration and recovery

Skin changes and fatigue can occur but mostly settle once treatment ends. Most patients can fly home within days of the last session.

Response assessment and follow-up continue remotely once you are home.

Cost

Korean national insurance covers some cancers for residents; international patients pay the hospital's international rate. Because it varies widely by cancer type and number of sessions, the cost is confirmed by quote.

The review fee is credited against your bill when you go ahead with treatment.

In Korea

Korea runs two proton centres, with more due from 2028. Paediatric proton therapy is a long-established field in Korea.

Hospital names and results are not listed here; the opinion compares three hospitals for you.

Frequently asked questions

Can children be treated?
Yes. Childhood cancer is one of the main indications. A paediatric anaesthesia team is on hand when sedation is needed, and the concierge helps with family accommodation and schooling.
Which is better, protons or carbon ions?
Neither is better in itself — only better suited. Where sparing healthy tissue comes first, protons are considered; where radiation resistance is the issue, carbon ions. The opinion states which applies to you.
Why is the stay long?
It comes down to the number of sessions: 10–35 at five a week works out at 4–7 weeks. Accommodation is arranged within walking distance of the hospital.

Clinical trials recruiting in Korea auto-updated · 2026-09-29

Fetched daily from ClinicalTrials.gov. Whether you can take part is answered in the opinion, based on stage.

NCTPhaseSponsorUpdated
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874
PHASE1Pheon Therapeutics2026-09-29
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784
PHASE3Revolution Medicines, Inc.2026-09-29
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517
PHASE3Boehringer Ingelheim2026-09-29
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597
PHASE1/PHASE2Merck Sharp & Dohme LLC2026-09-29
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339
PHASE3Merck Sharp & Dohme LLC2026-09-29
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898
PHASE3GlaxoSmithKline2026-09-28

Statistics on this page are official national statistics, not the results of any particular hospital. Outcomes differ by stage and by individual health. Discuss diagnosis and treatment decisions with your physicians.

So this site's information appears first in Google SearchAdd as a preferred source on Google

Get a written opinion

Upload your records; tertiary-hospital physicians read them, and within 5 business days you receive an opinion, three hospitals and an estimate.

Request a review Guides

Talk to a coordinator

If you have questions before the review, leave an inquiry on this site. A coordinator replies within 24 hours.

Book a call
Leave an inquiryRequest a reviewBook a call